This is a recording of a session from the AMP 2019 Annual Meeting & Expo. Purchase the entire AMP 2019 Annual Meeting & Expo Recordings for a significant discount!
New technology based on microfluidic devices are being developed for the isolation and preservation of circulating tumor cells for downstream applications, and to be able to use them to advance precision cancer medicine.
Advances in Liquid Biopsy: Isolation, Analysis and Expansion of CTCs
Sunitha Nagrath, PhD, University of Michigan, Ann Arbor, MI, USA
Microfluidic Platforms for the Efficient Isolation of Circulating Leukemia Cells and Circulating Plasma Cells
Steven A. Soper, PhD, The University of Kansas, Lawrence, KS, USA
Objectives:
- Understand new technology forseparation and preservation of CTCs for downstream applications.
- Introduce a description of the new microfluidic devices being developed and describe the operational parameters of these devices for the selection of liquid biopsy markers.
- Describe the downstream molecular information that can be garnered from the isolated markers in diseases such acute myeloid leukemia (circulating leukemia cells) and multiple myeloma (circulating plasma cells). Using liquid biopsy markers for these two diseases circumvents the need for a painful bone marrow biopsy. Information will be provided on using these liquid biopsy markers to monitor relapse from minimum residual disease, and staging patients for directing therapy (i.e., precision medicine).
Duration: 1.50 hr
Recording Date: November 8, 2019
CME/CMLE credit: 1.50 hr
Last day to purchase course and CE claim credit: December 24, 2022
